Saturday 17 October 2026
Export GDTC’s income statement to Excel — free account
CytoMed Therapeutics Limited
GDTC Healthcare Biotechnology
CytoMed Therapeutics Limited’s revenue for fiscal 2025 (year ended December 2025) was $252,300.00, up 395.7% from fiscal 2024. Insiders bought in the last twelve months.
0.88
0.01
+1.15%
Follow GDTC
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+7 more quarters Free account |
9.89 | 5.81 | 5.17 | 2.64 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
4.53% | 5.63% | 5.80% | 6.18% | |
Debt/Equity |
0.05 | 0.07 | 0.07 | 0.08 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | — | |
Capex/Depreciation |
(4.18) | (1.94) | (1.59) | — | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.02 | 0.01 | |
Share Based Compensation of Revenue |
— | 0.00% | — | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | — | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(3.01) | (1.53) | (3.37) | — | |
Working Capital |
3.95 | 2.66 | 2.30 | 1,554.77 | |
Capital Expenditures |
(1.02) | (0.27) | (0.50) | — | |
Net Current Asset Value |
3.64 | 2.32 | 1.97 | 1,252.07 | |
| Other line items | |||||
Quick Ratio |
9.89 | 5.81 | 5.17 | 2.64 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | — | |
Capex per Share |
0.00 | 0.00 | 0.00 | — | |
Average Receivables |
0.72 | 0.86 | 1.03 | 687.16 | |
Average Payables |
0.32 | 0.29 | 0.37 | 399.13 | |
Average Assets |
5.63 | 8.43 | 7.79 | 2,714.44 | |
Average Common Equity |
3.53 | 7.71 | 6.93 | 2,089.88 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 2 Oct 2026